Dg Anti-itch

Diphenhydramine Hydrochloride And Zinc Acetate


Dollar General
Human Otc Drug
NDC 55910-344
Dg Anti-itch also known as Diphenhydramine Hydrochloride And Zinc Acetate is a human otc drug labeled by 'Dollar General'. National Drug Code (NDC) number for Dg Anti-itch is 55910-344. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Dg Anti-itch drug includes Diphenhydramine Hydrochloride - 20 mg/g Zinc Acetate - .1 mg/g . The currest status of Dg Anti-itch drug is Active.

Drug Information:

Drug NDC: 55910-344
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dg Anti-itch
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Diphenhydramine Hydrochloride And Zinc Acetate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Dollar General
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DIPHENHYDRAMINE HYDROCHLORIDE - 20 mg/g
ZINC ACETATE - .1 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 17 May, 2011
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Dollar General
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:TC2D6JAD40
FM5526K07A
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Copper Absorption Inhibitor [EPC]
Decreased Copper Ion Absorption [PE]
Histamine H1 Receptor Antagonists [MoA]
Histamine-1 Receptor Antagonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
55910-344-241 TUBE in 1 CARTON (55910-344-24) / 28 g in 1 TUBE19 Oct, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Active ingredients purposes diphenhydramine hydrochloride 2% topical analgesic zinc acetate 0.1% skin protectant

Product Elements:

Dg anti-itch diphenhydramine hydrochloride and zinc acetate diphenhydramine hydrochloride diphenhydramine zinc acetate zinc cation cetostearyl alcohol polysorbate 60 dmdm hydantoin glyceryl monostearate isopropyl myristate phenoxyethanol mineral oil sodium benzoate water

Indications and Usage:

Uses temporarily relieves pain and itching associated with: insect bites minor burns sunburn scrapes minor skin irritations minor cuts dries the oozing and weeping of poison ivy, poison oak and poison sumac

Warnings:

Warnings for external use only. avoid contact with eyes. do not use more than directed on large areas of the body with any product containing diphenhydramine even one taken by mouth ask a doctor before use on chicken pox on measles stop use and ask a doctor if condition worsens or does not improve within 7 days symptoms persist for more than 7 days or clear up and occur again within a few days if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away: 800-222-1222.

Do Not Use:

Warnings for external use only. avoid contact with eyes. do not use more than directed on large areas of the body with any product containing diphenhydramine even one taken by mouth ask a doctor before use on chicken pox on measles stop use and ask a doctor if condition worsens or does not improve within 7 days symptoms persist for more than 7 days or clear up and occur again within a few days if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away: 800-222-1222.

Dosage and Administration:

Directions do not use more than directed adults and children 2 years of age and older: apply to affected area up to 4 times daily children under 2 years of age: ask a doctor

Stop Use:

Stop use and ask a doctor if condition worsens or does not improve within 7 days symptoms persist for more than 7 days or clear up and occur again within a few days

Package Label Principal Display Panel:

Principal display panel - 28 g tube carton dg™|health ndc 55910-344-24 compare to active ingredients of benadryl ® extra strength cream* extra strength anti-itch cream topical analgesic and skin protectant relieves itches from insect bites & skin irritations net wt 1 oz (28 g) principal display panel - 28 g tube carton

Further Questions:

Questions or comments? 1-888-309-9030


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.